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ABSTRACT
Triple-negative breast cancer (TNBC) is defined by the lack of expression of 
the oestrogen and progesterone receptors and HER-2. Recently, carbon monoxide 
(CO) was found to behave as an important endogenous signalling molecule and to 
suppress VEGF receptor-2 (VEGFR-2) and protein kinase B phosphorylation. Given 
that anti-angiogenic drugs exist as one of the few available targeted therapies 
against TNBC, the aim of this project was to study the effects of CO-releasing 
molecules (CORMs) on TNBC cell lines and the associated endothelial cells and 
characterise their anti-angiogenic properties that can be used for the reduction of 
cancer-driven angiogenesis. Four commercially available CORMs were screened for 
their cytotoxicity, their effects on cell metabolism, migration, VEGF expression, tube 
formation and VEGFR-2 activation. The most important result was the reduction 
in VEGF levels expressed by CORM-treated TNBC cells, along with the inhibition 
of phosphorylation of VEGFR2 and downstream proteins. The migration and tube 
formation ability of endothelial cells was also decreased by CORMs, justifying a 
potential re-purposing of old CORMs towards the anti-angiogenic therapy of TNBC. 
The additional favourable low cytotoxicity, reduction in the glycolysis levels and 
downregulation of haem oxygenase-1 in TNBC cells enhance the potential of CORMs 
against TNBC. In this study, CORM-2 remained the most effective CORM and we 
propose that CORM-2 may be pursued further as an additional agent in combination 
with existing anti-angiogenic therapies for a more successful targeting of malignant 
angiogenesis in TNBC.
INTRODUCTION
Cancer deriving from the mammary gland (breast 
cancer) affects more than 1.3 million women worldwide 
each year, with more than 55,000 reported cases in the 
U.K. in 2015 (Cancer Research UK). The increasing 
occurrence, complexity and heavy economic burden 
of the required treatment to the overall health system 
expenditure make breast cancer one of the most urgent 
health issues in our society [1, 2]. Although most types 
of breast cancer express hormone receptors (HR), there 
is a distinct subtype called triple-negative breast cancer 
(TNBC) that lacks the immunohistochemical expression 
of oestrogen receptor (ER), progesterone receptor (PR) 
and the HER2/neu protein or amplification of the HER2/
neu gene. Clinical data reveal that approximately 15% of 
all breast cancers are diagnosed as TNBC, which occurs 
more frequently among minority (black race, Hispanic 
ethnicity) and younger women (<40 years old) and is 
characterized by high histological grade, higher risk 
of distant recurrence and shorter disease-free survival 
than ER-positive subtypes, alongside a more frequent 
metastasis to bone, lung and brain [3–5].
This unique subtype of breast cancer has yet 
no established effective therapeutic regimens, and the 
most frequently prescribed drugs are a combination of 
chemotherapeutic agents and receptor tyrosine kinase (RTK) 
inhibitors. However, the results remain disappointing and 
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lack long-term effectiveness [6]. Angiogenesis is the multi-
step process of new capillary formation from pre-existing 
blood vessels and plays a pivotal role in physiological 
processes, but it has also been recognized as a prerequisite 
for tumour growth, progression and metastasis [7, 8]. The 
angiogenic process has recently emerged as a promising 
target for TNBC, where it seems to be significantly over-
activated and supports the growth and metastasis of the 
primary tumour [9, 10]. It is well established that one of the 
main growth factors regulating angiogenesis is the vascular 
endothelial growth factor (VEGF), upon interaction with its 
principal receptor VEGF-receptor-2 (VEGFR2) [11, 12]. 
VEGF itself is abundantly secreted by breast cancer cells in 
order to promote differentiation and aggressive phenotypes. 
By overexpressing VEGF, TNBC cells succeed in 
stimulating angiogenesis conducted by the adjacent vascular 
endothelial cells (ECs) and providing further nourishment 
for the growing tumour, the remove of the waste as well 
as the entering point of the distinct metastasis. Therefore, 
targeting the interaction between VEGF and VEGFR2, as 
well as other downstream kinases might not only help in 
developing better therapies for TNBC, but also overcome 
the chemo- and radiation resistance correlated with TNBC 
[13]. Since recent investigations into the use of anti-VEGF 
therapies such as bevacizumab alongside chemotherapy 
have ultimately proved ineffective in the long-term for 
patients with invasive breast cancer, and given the status 
of anti-VEGF drugs as one of the few available targeted 
therapies for TNBC, there remains an urgent and unmet 
medical need for improving the existing anti-angiogenic 
therapies [14].
For a long time, carbon monoxide (CO) has been 
best known for its toxic effect as an air pollutant because of 
its strong affinity (>220-fold greater than that of oxygen) 
for the iron of haemoglobin. However, endogenously 
produced CO by haem oxygenases (HO) was found to 
regulate various molecular signalling pathways related, 
among others, to cellular metabolism, and was therefore 
characterized a gasotransmitter [15, 16]. However, since 
the administration of CO gas can be dangerous and poorly 
regulated, the discovery of transition metal carbonyls 
that can act as CO-releasing compounds (CORMs) 
has provided a safer way to control CO release in vivo 
in a spatial and temporal manner [17]. Previous studies 
suggested that CO can have various and even opposite 
effects on different subtypes of cancer and CORMs might 
act as a new therapeutic entity [18–20]. Additional to the 
observed heterogeneous effects on different systems and 
cell types, recent research has also demonstrated that the 
ruthenium-based first generation CORM-2, can exhibit 
anti-angiogenic activity by inhibiting VEGF-induced EC 
functions and the activation of VEGFR2 [21].
Based on the above observations, we designed this 
study to shed more light on potential anti-angiogenic 
properties of CORMs in a TNBC subset. Since CORM-
2 has been thoroughly tested in various cell models 
with contradicting results, three other first and second 
generation CORMs were also tested in our study and 
compared with CORM-2. Here we reported the novel 
observations of the anti-angiogenic activity of CORMs 
that will eventually help in elucidating the mechanism 
of action of these unique organometallic complexes as 
anti-angiogenic agents. In the term of anti-angiogenic 
activity, CORM-2 remained the most effective CORM and 
we propose CORM-2 as a potential agent to be pursued 
further in combination with existing anti-angiogenic 
therapies for a more successful targeting of malignant 
angiogenesis in TNBC.
RESULTS
CORMs reduce VEGF expression in TNBC cells
In order for tumour angiogenesis to take place, 
two important steps must be accomplished. First, the 
tumour cells should be able to express and secret high 
concentrations of VEGF and other growth factors, in order 
to induce pro-angiogenic signals. Second, vascular ECs 
around the tumour area should express effective VEGFRs 
(RTKs) that upon binding with VEGF will initiate the pro-
angiogenic signal through activation of their downstream 
signalling pathways. This activation cascade involves the 
phosphorylation of several kinases that manipulate EC 
survival, proliferation, migration and vessel formation. 
Therefore, an anti-angiogenic agent could potentially 
inhibit several different steps of this process, either the 
ability of cancer cells to express the elevated levels of 
the pro-angiogenic molecules or the ability of ECs to 
execute an efficient signal transduction that leads to new 
vessel formation. In that scope, CORMs were subjected 
to relevant experiments in order to assess their ability to 
affect both required steps for successful angiogenesis.
MDA-MB-231 cells were treated with CORMs and 
the concentration of VEGF excreted in the cell culture 
supernatant was quantified with a human VEGF ELISA 
kit. As observed in Figure 1A, all four CORMs reduced 
the concentration of excreted VEGF in MDA-MB-231 
cells. More specifically, in the 6 h treatment CORM-3 
reduced VEGF by more than 55% reaching high statistical 
significance and CORM-2 followed as the second most 
effective one. The reduction in the expression of VEGF 
in MDA-MB-231 cells remained evident even in the 
longer time treatments. In the 12 h treatment, CORM-
2 proved the most efficient, reducing VEGF expression 
by 60% with the greatest statistical significance among 
the others, but CORM-3 remained extremely successful. 
Finally, in the 24 h treatment, the results were similar, 
with CORMs -2 and -3 reducing the concentration of 
the excreted VEGF by 65% and 50%, respectively, with 
high statistical significances. Subsequently, these CORMs 
were also tested at a higher concentration of 250 µM, to 
seek for concentration-dependent effects (Figure 1B). 
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Figure 1: VEGF expression after CORM treatments. (A) Quantification of VEGF levels in the supernatants of treated MDA-
MB-231 cells with 100 µM CORMs or vehicle or normal media for 6 h, 12 h or 24 h. (B) Quantification of VEGF levels in the supernatants 
of treated MDA-MB-231 cells with 250 µM CORMs or vehicle or normal media for 6 h, 12 h or 24 h. (C) Quantification of VEGF levels 
in the supernatants of treated MDA-MB-436 cells with 100 µM CORMs or vehicle or normal media for 6 h, 12 h or 24 h. (% percentage 
compared to media treated cells (control) ±SEM; n = 3, N = 3) (All data was statistically analysed against media treated cells using unpaired 
t-test with Welch’s correction: *p < 0.05, **p < 0.01, ***p < 0.001).
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However, only CORM-2 appeared to reduce VEGF 
expression in a significantly higher level compared to the 
lower concentration, but this could also be a cytotoxicity-
linked result, so the effect was not deemed concentration-
dependent.
The other TNBC cell line involved in this study, 
MDA-MB-436, was also studied for similar reduction 
effects and the results of 100 µM treatments at three 
different time points are depicted in Figure 1C. CORM-2 
and CORM-3 were the most successful in decreasing the 
excreted VEGF, although higher variations were reported 
for this cell line leading to lower statistical significance. 
CORM-2 was the only CORM that raised significantly 
different results compared to control at all time points. 
However, a similar trend was observed for both TNBC 
cell lines.
CORM-2 and CORM-3 abrogate the 
phosphorylation of downstream proteins of 
the VEGFR2 signalling pathway in VEGF 
stimulated HUVEC cells
Within the tumour microenvironment, the VEGF 
excreted by cancer cells binds to its receptors on the EC 
surface. Upon binding, the receptor auto-dimerizes and 
transfers the pro-angiogenic signal within the EC, through 
consecutive phosphorylation of downstream kinases [22].
Since the successful downstream transfer of the 
angiogenic signal is vital to the vessel formation activity 
of ECs, we aimed to investigate the ability of the two most 
promising CORMs, CORM-2 and CORM-3 to inhibit the 
activation of some of these kinases in primary vascular 
ECs (HUVEC) upon VEGF stimulation. The first target, 
VEGFR2, has multiple phosphorylation sites, but Y1175 
was chosen. Therefore, an ELISA quantification was 
performed for the phosphorylation levels of VEGFR2 
at Y1175 upon CORM or vehicle pre-treatment and 
VEGF stimulation, and as shown in Figure 2A, CORM-
2 managed to return the phosphorylation at the baseline 
levels of the unstimulated control (Control). This reduction 
reached high statistical significance. CORM-3 failed to 
decrease these levels, and the same result was also verified 
via a Western blot analysis, suggesting that only CORM-2 
could inhibit the phosphorylation of Y1175 of VEGFR2 
(Figure 2B).
Some downstream proteins were also chosen to 
be tested via Western blot analysis. As shown in Figure 
3A and 3B, both CORM-2 and CORM-3 significantly 
downregulated the phosphorylation of ERK1 and ERK2 
at baseline levels. On the contrary, the phosphorylation 
of Src at Y419 was not significantly inhibited by the two 
CORMs, although the stimulation achieved with this 
protocol was very moderate for Src (measured increase 
of the phosphorylation by ~50% for the control and 
~25% for the vehicle compared to the Control) (Figure 
3B). Finally, FAK was also mildly stimulated by VEGF 
leading to no statistical significance for the reduction in 
the phosphorylation levels of Y397 produced by CORM-
2, but the trend of downregulation was again observed 
(Figure 3B).
Reduction in VEGF expression by TNBC cells 
leads to lower tube formation ability of ECs
As outlined thoughout this work, angiogenesis 
is central to many normal physiological processes, but 
Figure 2: pY1175 levels after CORM treatments. (A) Expression levels of pY1175 of VEGFR2 in HUVEC after 15 min of CORM 
or vehicle pre-incubation and then stimulation with VEGF (100 ng/ml) for 5 min (SFM), as measured with the human pY1175-VEGFR2 
ELISA kit. The first sample is the unstimulated control (Control). (Graph shows % compared to Control ±SEM; N = 3) (Data statistically 
analysed using unpaired Student’s t-test with Welch’s correction *p < 0.05, **p < 0.01). (B) Representative blot of the levels of pY1175 of 
VEGFR2 following the same protocol (N = 3).
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Figure 3: Expression of VEGFR2 pathway proteins in HUVEC after CORM pre-treatments and VEGF stimulation. 
(A) Western blot of pFAK, pSrc and pERK1/2 following 15 min of CORM or vehicle pre-incubation and then stimulation with VEGF (100 
ng/ml) for 5 min (SFM). The first sample is the unstimulated control (Control). (Blots show representative data; N = 3). (B) Quantitative 
assessment of pFAK, pSrc and pERK1/2 levels in HUVEC. (Graphs show % compared to Control ±SEM; N = 3) (Data statistically analysed 
using nonparametric (Mann-Whitney) t-test with *p < 0.05, **p < 0.01).
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has also been linked to tumour growth, progression and 
metastasis [7, 23]. The prevalent form of pathological 
angiogenesis is sprouting angiogenesis, which participates 
in tumour neovascularization [11].
Since VEGF is the major mediator of angiogenesis 
and the interaction between VEGF and its receptors 
facilitates tumour growth especially in TNBC, we, 
therefore, studied the CORM-mediated effect of the 
reduction in VEGF expression from TNBC cells on the tube 
formation ability of ECs. Conditioned media from CORM-
treated MDA-MB-231 cells were used to stimulate tube 
formation in HECV cells. As shown in Figure 4A and 4B, 
conditioned media from CORM-1, CORM-2 and CORM-
3 treatments managed to reduce the formation of tubes 
by ECs, with CORM-2 and CORM-3 reaching statistical 
significance. The tubes observed were fewer and longer 
compared to vehicle and control groups.
CORM-2 directly eliminates the tube formation 
ability of ECs
To investigate the direct effect of CORMs on the 
tube formation ability of ECs, a separate experiment was 
conducted, where ECs were directly treated with the CORMs 
or vehicle or serum free media and their tube formation 
capability was assessed by quantifying total tube length in 
images taken 6 h after treatments. As shown in Figure 5A and 
5B CORM-2 completely eliminated the formation of tubes 
with high statistical significance, whereas the other tested 
CORMs did not produce such a significant inhibition.
Figure 4: Tube formation ability of HECV after conditioned media treatments. (A) Representative images from tube formation 
assay with HECV cells treated with conditioned media from variable duration incubation of MDA-MB-231 cells with 100 µM CORMs or 
vehicle or normal media. Objective 5x, Scale bar = 132.08 µm. (B) Quantification of tube formation capacity of HECV cells after treatment 
with conditioned media. (% Total tube perimeter compared to vehicle ±SEM; n = 3, N = 3) (All data was statistically analysed against the 
conditioned media from corresponding duration vehicle treated MDA-MB-231 cells using un-paired t-test with Welch’s correction: *p < 
0.05, **p < 0.01, ***p < 0.001).
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CORMs inhibit the migration of ECs
Angiogenesis is directly linked to the capability 
of ECs to proliferate and migrate in response to growth 
factor activation. There is a fine balance between pro- 
and anti-angiogenic factors that determines the formation 
of new blood vessels, not only in a normal environment 
but also in a cancerous one. In this process, migration 
of capillary ECs plays a major role and it follows the 
stimulation induced by the secreted and circulating VEGF 
[24]. Finding agents that can disrupt the migration of ECs 
would be a promising alternative approach towards the 
inhibition of cancer-mediated angiogenesis.
For these reasons, the four available CORMs were 
tested for their ability to inhibit the migration of ECs 
following a wound formation on their monolayer. Figure 
6A present the results of a traditional scratch wound assay 
in ECs after CORM, vehicle or media treatments. As 
observed, CORM-1, CORM-2 and CORM-3 blocked the 
migration of ECs, leaving the induced wound still open, 
Figure 5: Tube formation ability of HECV after CORM treatments. (A) Representative images from tube formation assay 
with HECV cells treated with 100 µM CORMs or vehicle or serum free media. Objective 5x, Scale bar = 132.08 µm. (B) Quantification of 
tube formation capacity of HECV cells after treatment with CORMs or vehicle or serum free media. (% total tube perimeter compared to 
vehicle ±SEM; n = 3, N = 3) (All data was statistically analysed against the vehicle group using un-paired t-test with Welch’s correction: 
*p < 0.05, **p < 0.01).
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even 24 h after the scratch (Figure 6A). This inhibition 
reached significance at the final time point of 24 h for all 
three CORMs, as calculated in an un-paired t-test with 
Welch’s correction and depicted in Figure 6C. It should 
be noted though, that the migration of the vehicle treated 
cells was delayed compared to the control group, and 
this difference reached significance with p = 0.0056, 
as calculated in a two-way ANOVA test (Figure 6B). 
However, the wound managed to close anyway after 24 h.
CORMs express moderate cytotoxicity against 
TNBC, epithelial and EC lines
According to general opinion, heavy metals and 
drugs based on them may present toxicological concerns 
not only to the environment in general, but also to different 
cells and organisms. The same applies to organometallic 
compounds with different metals bound, but the toxic 
effects derive mainly from the intrinsic characteristics of 
each one, such as the oxidation state, ligand sphere or the 
counter-ion present [25]. CORMs are a special class of 
organometallic complexes, as the CO presents additional 
toxicological hazards that should not be overlooked.
Therefore, the two TNBC cell lines, MDA-MB-231 
and MDA-MB-436, along with the MCF-10A breast 
epithelial cells and HECV immortalized ECs were 
assessed for their viability upon CORM treatments for 72 h 
using the MTT colorimetric assay. No major cytotoxicity 
compared to the vehicle was observed against these cell 
lines and the calculated IC50 values exceeded 100 µM 
(Supplementary Figure 1A). Only CORM-2 provoked 
toxicity in MCF-10A cells with a calculated IC50 value 
of 31.87 µM. Following this, the 100 µM concentration 
was chosen for further studies and the % percentage cell 
viability for each CORM and cell line at this concentration 
can be seen in Supplementary Figure 1B.
CORM-2 decreases the glycolytic metabolism of 
TNBC cells
In 1924 Otto Warburg realized that cancer cells 
depend on aerobic glycolysis to metabolize glucose and 
generate ATP. This phenomenon is referred to as the 
“Warburg effect” [26]. The up to 200 times higher rate 
of glycolysis in cancer cells is followed by lactic acid 
fermentation in the cytosol, unlike normal cells which 
Figure 6: Migratory ability of HECV after CORM treatments. (A) Representative images from a scratch wound assay in HECV 
cells at 0 h and 24 h after treatment with 100 µM CORMs or vehicle or normal media. Objective 5x, Scale bar = 100.37 µm. (B) Assessment 
of the healing, expressed as % wound confluence, at all time points tested after treatments. (% wound confluence ±SEM; n = 3, N = 3) 
(All data was statistically analysed against vehicle treated cells using two-way ANOVA: *p < 0.05, **p < 0.01, ***p < 0.001). (C) Average 
% wound confluence at the final time point (24 h) for all treatments. (All data was statistically analysed against the vehicle group using 
un-paired t-test with Welch’s correction: *p < 0.05, **p < 0.01, ***p < 0.001).
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oxidize pyruvate in mitochondria [27]. This observation 
of high glycolysis levels of cancer cells compared to 
normal cells, was deemed a promising target for new anti-
cancer therapies. Inhibition of glycolysis would deprive 
cancer cells of energy, reducing their rapid growth and 
proliferation [28, 29].
With this in mind, investigation into whether 
this metabolic modulation was evident in TNBC cells 
upon CORM treatments was desired and a Seahorse XF 
Glycolysis Stress Test was conducted. MDA-MB-231 
cells were chosen due to being a highly aggressive 
and metastatic TNBC cell line [30, 31]. In the two 
concentrations tested (100 µM, 50 µM), only CORM-2 
raised a statistically significant reduction in the glycolysis 
change rate compared to the vehicle group with a very 
high statistical significance for the higher concentration. 
Other CORMs did not show any significant effect on the 
glycolytic metabolism of TNBC cells (Supplementary 
Figure 2).
CORMs decrease HO-1 expression in MDA-
MB-231 cells
Haem oxygenase-1 (HO-1) is a well-characterised 
cytoprotective enzyme that defends the cell in conditions 
of oxidative stress and excessive ROS production [32]. 
CORMs have been reported to increase ROS production, 
especially in bacterial, but also in eukaryotic cells [33].
Therefore, this study aimed to investigate whether 
CORMs could potentially alter the expression of this 
enzyme, affecting the redox status of the cancer cells 
and their antioxidant defence systems. MDA-MB-231 
cells were treated with 100 µM CORMs for 12 h and 
the expression of HO-1 was quantified via Western blot 
analysis. As observed in Supplementary Figure 3A and 
3B, CORM-1 and CORM-2 significantly reduced the 
expression of HO-1 after 12 h of treatment, whereas 
CORM-3 failed to reach this level of significance, even 
though the same reducing trend was observed. On the 
other hand, CORM-A1 increased the expression of this 
enzyme by 40%, indicating a different mechanism of 
interaction with the HO-1 system than the other CORMs.
DISCUSSION
The aim of this study was to screen four 
commercially available first and second generation 
CORMs for effects against TNBC. With this in mind, 
several experiments were conducted trying to relate 
these complexes to anti-angiogenic activities, such as 
effects on the stimulant activity of TNBC cells per se or 
on the signalling and migratory activities of ECs that are 
responsible for the angiogenic process.
Tumour angiogenesis refers to the highly interactive 
process of the formation of new blood vessels from pre-
existing ones. It is linked to the expression of several 
proteins, both by the cancer cells themselves and by the 
ECs that line the surrounding blood vessels and execute 
the process of neovascularization [34]. A logical approach 
would be to combine agents that can reduce the expression 
of angiogenic factors with ones that target these factors 
per se, or their receptors. The principle behind this 
combination involves the potential enhancement of 
the delivery of cytotoxic agents to the tumour site, as 
well as the possible interference with the ability of the 
tumour to recover from the effects of the accompanying 
chemotherapeutic agent [35]. With this in mind, the next 
step of the screening of the four commercially available 
CORMs was to measure the expression of proteins 
related to angiogenesis and responsible for its successful 
accomplishment.
The main pro-angiogenic factor, VEGF, participates 
in the angiogenic process by increasing vascular 
permeability and stimulating EC survival, proliferation, 
migration and expression of MMPs among others [34]. 
Intriguingly, some reports suggested an increase in VEGF 
expression induced by CORMs in several in vitro models. 
More specifically, ECs seemed to stimulate their VEGF 
expression upon treatment with CORMs, CORM-2 and 
CORM-3 in most studies, and this pointed towards an 
increased angiogenic potential for these cells [36, 37]. 
Other cells showed a similar behaviour. For instance, 
CORM-2 caused an increase in VEGF secretion in 
astrocytes [38] and CORM-401 and CORM-A1 led to an 
enhanced expression of VEGF in microglia cells after 3 h 
of treatment, whereas after 6 h the levels returned back to 
normal [39]. However, there are also studies contradicting 
these results, such as the study from Ahmad et al. [21] 
where HUVEC – primary vascular ECs – were reported 
to downregulate the phosphorylation and activation of 
both VEGFR2 and AKT upon treatment with CORM-
2, suggesting a potential anti-angiogenic ability of this 
compound. Nevertheless, none of these studies included 
cancer cells, and there are extensive reports that the effects 
of CO and CORMs are cell and tissue-type specific. [19] It 
was deemed useful to study the effects of the commercially 
available CORMs on the expression of VEGF from TNBC 
cells.
The reduction in VEGF reached a level of 50–60% 
in this study, suggesting a very promising profile for these 
complexes that can potentially halt the elevated expression 
of VEGF by TNBC cells, possibly also decreasing the 
angiogenic stimulation reaching the surrounding ECs. 
It would be important to mention that these results were 
significant, and all four CORMs seemed to share the same 
tendency to reduce the VEGF expression of TNBC cells 
in a dose-dependent manner for CORM-2. However, it 
should be considered whether this reduction was a direct 
effect of potential cellular toxicity of this compound. Thus, 
the main observation of this experiment was the reduction 
in the excreted VEGF from TNBC cells at all time points 
tested, leading to potentially decreased angiogenic 
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stimulation towards ECs. These complexes were shown to 
interfere with the expression pathway of VEGF in TNBC 
cells, possibly leading to lower stimulation signals to the 
surrounding tissues. There are differences in the VEGF 
expression and regulation mechanisms between TNBC 
and normal breast cells. Hence, this altered mechanism 
might well be prone to CORM interference.
According to general opinion, heavy metals and drugs 
based on them may present toxicological concerns not only 
to the environment in general, but also to different cells and 
organisms. Metal toxicity, however, is tightly correlated 
with the form in which the metal is present, as pure elements 
may differ greatly from their solubility, oxidation state and 
bioavailability variations [25]. Organometallic compounds 
are a special class of molecules, especially CORMs that are 
able to release CO, and a toxicological investigation should 
be conducted before conclusions about their activities can 
be safely reached.
In the assessment of cytotoxicity for the four 
commercially available CORMs the two TNBC cell lines, 
MDA-MB-231 and MDA-MB-436, along with the control 
epithelial breast cell line, MCF-10A, and the vascular 
EC line, HECV, were tested. These compounds exerted 
a moderate cytotoxicity against the cell lines, with the 
most potent compound in general being CORM-2. As 
found in previous studies, CORM-2 was toxicity against 
different cell subtypes at 50 µM [21, 40, 41]. The toxicity 
of CORM-2 against ECs along with TNBC cells might be 
desired, but the quite high toxicity against breast epithelial 
cells is definitely a drawback. However, Ru compounds 
are generally believed to cause fewer and less severe side 
effects compared to other organometallic drugs, and they 
have shown broad diversity in their activity, toxicity and 
mechanisms of action [42–44].
CORM-3 on the other hand, even though sharing 
many common features with CORM-2, such as the Ru core 
and the similar ligand sphere, exerted a considerably lower 
toxicity against the tested cells. It appeared to be more 
potent against MDA-MB-231, and almost no cytotoxicity 
was reported against epithelial or ECs, suggesting a kind 
of selectivity for this CORM.
CORM-1 was the other first generation CORM 
tested, which also belongs to the photo-CORM family. 
We observed that the two TNBC cells were more sensitive 
compared to the epithelial or endothelial ones. Finally, 
CORM-A1 did not show any cytotoxicity against the 
tested cells and it is also the only one without a heavy 
metal core. Therefore, the metal core may be partly 
responsible for the moderate toxicity associated with 
CORMs -1, -2 and -3, although no major cytotoxicity 
was reported for any of the cells involved. This is also 
an indication that the heavy metal core is not necessarily 
toxic in all potential forms, and that other characteristics 
may affect this behaviour.
Another important aspect of angiogenesis is the 
successful pro-angiogenic signal transduction from the 
surface receptor VEGFR2 to its complex network of 
downstream proteins [7]. VEGF has a higher affinity for 
VEGFR1, but the effects of activation are much more 
profound for VEGFR2, regulating EC functions [12]. 
VEGFR2 has also been found upregulated in TNBC [9, 
10, 45]. As an RTK, VEGFR2 undergoes dimerization 
and oligomerization, which results into auto- and trans-
phosphorylation on specific tyrosines in the cytoplasmic 
domain. Two of the most important tyrosine residues 
(autophosphorylation sites) are Y1175 and Y1214 [46, 47]. 
Therefore, CORMs were studied for their ability to reduce 
the phosphorylation of one of these tyrosine residues of 
VEGFR2, in order to investigate any inhibitory activity 
on the activation of this major receptor. Intriguingly, we 
demonstrated that only CORM-2 appeared to inhibit 
the activation of this receptor on Y1175, reducing the 
phosphorylation almost to baseline levels in a statistical 
manner, whereas CORM-3 failed to produce such an 
inhibition, pointing towards a very promising behaviour 
of CORM-2. This was a particularly interesting finding 
that correlates well with previous literature [21, 48] 
and suggests an impairment of the angiogenic signal 
transduction after treatment with CORM-2, even upon 
stimulation with a high dose of VEGF that is far higher 
than the normal VEGF concentrations in the tumour 
microenvironment [49].
As a proof of concept, more downstream proteins 
were investigated upon stimulation with VEGF, in order to 
shed light on any potential targets of CORM-2 and CORM-
3 [34]. Different studies reported contradictory results. 
The work done by Otterbein et al. [50] and Brouard et al. 
[51] suggested an upregulation of pERK1/2 in stimulated 
macrophages, fibroblasts and ECs upon treatment with 
CO gas, whereas Song et al. [52] showed an inhibition 
of ERK phosphorylation in stimulated human gingival 
fibroblasts upon treatment with CORM-3. Taillé and 
colleagues [53] found decreased ERK1/2 phosphorylation 
in airway smooth muscle cells upon treatment with 
CORM-2, which implicated ROS production. Therefore, 
we studied HUVEC cells for the phosphorylation levels 
of different proteins of the VEGFR2 pathway upon VEGF 
stimulation and found that CORM-2 and CORM-3 exerted 
a differential inhibitory activity. For example, CORM-2 
was effective in inhibiting the phosphorylation of all tested 
proteins reaching significance for ERK1/2. Even though a 
similar downregulating activity was observed also for Src 
and FAK proteins, this did not reach significance probably 
due to the quite mediocre activation of these proteins 
under the given conditions. CORM-3, on the other hand, 
was shown to be preferentially effective against ERK1/2. 
This suggested a different mechanism of action for the 
two CORMs of similar chemical structure, but anyway 
confirmed their potential as anti-angiogenic agents.
Commercially available CORMs seemed to induce 
a modest reduction in the levels of VEGF expressed 
by TNBC cells. Following this, it was speculated that 
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these decreased levels of growth factor would have a 
subsequent decreasing effect on the ability of ECs to form 
tubes. Conditioned media from CORM treated TNBC 
cells stimulated angiogenesis at a lower level compared 
to vehicle or media treated cells, suggesting a potential 
inhibition of the capability of ECs to form tubes. CORM-2 
had the most profound effect and the second best CORM 
was CORM-3.
As CORM-treated TNBC conditioned media 
showed less angiogenic stimulation than non-treated 
conditions, we asked a question whether CORMs possess 
a direct effect on the angiogenic functions of ECs. When 
a tube formation experiment was conducted with direct 
CORM treatments on ECs, CORMs -1, -3 and -A1 did not 
reduce tube formation in a significant manner, suggesting 
a minimal interference with the ECs themselves. However, 
CORM-2 treatment surprisingly reduced tube formation 
completely and further analysis revealed that CORM-2 
treated ECs remained stable and were unable to migrate 
and create capillary-like formations. Our migration results 
confirmed the notion that CORM-2 interfered with the 
ECs themselves and correlated well with the inhibition 
on migration previously shown for this compound [21]. 
This result suggested a strong anti-angiogenic behaviour 
of CORM-2 when in direct contact with ECs and should 
not be linked to the moderate toxicity of this compound 
towards HECV cells.
All these observations lead to a preliminary 
conclusion that these compounds and especially CORM-
2 can act anti-angiogenically. It is documented that other 
VEGFR inhibitors and monoclonal antibodies that target 
angiogenesis have generally failed to show significant 
overall efficacy in the clinic [54], therefore new drugs that 
can combine different mechanisms of action are currently 
pursued. CORMs could be such a drug, benefiting the 
anticancer therapy from many points, and as a part of a 
combination treatment enhance the activity of existing 
drugs such as other VEGFR or VEGF-A inhibitors. 
By combining the VEGF-decreasing activity with the 
VEGFR activation inhibition, CORMs can also help in the 
reduction of the dosage for existing anti-angiogenic drugs 
or lead to the reuse of revoked drugs for breast cancer, 
such as Avastin due to the non-significant improvement of 
patient survival and several side effects [55–57]. Limiting 
these side effects could lead to more effective and less 
harmful combination therapies that address malignant 
angiogenesis in many ways, also reducing the risk of 
resistance.
To expand the investigation of CORMs against 
TNBC, some other effects were also studied. These tests 
aimed to indicate other anti-TNBC properties of CORMs 
related to important cell functions such as viability, 
metabolism and HO-1 expression, which is a crucial 
cytoprotective enzyme.
Cancer has long been linked to mitochondrial 
dysfunctions. Aerobic glycolysis (Warburg effect) 
can be more efficient in supporting the rapid growth 
of cancer cells, compared to normal glycolysis linked 
to the TCA cycle and oxidative phosphorylation. In 
addition, diminishing mitochondrial activity offers cancer 
cells a way to reduce apoptosis, therefore provides an 
evolutionary advantage. The reprogramming of cellular 
metabolism and the shift of the environmental pH towards 
the acidic region during malignant transformation 
suppresses the growth of normal cells and potentially 
supports cancer cell growth and migration [29, 58].
CO has been shown to exert a variety of effects on 
mitochondrial function and cell metabolism, depending 
on its concentration, the duration of exposure and the 
specific cell subtype studied [59]. It is generally accepted 
that CO can inhibit cellular mitochondrial respiration 
via inhibition of complex IV (cytochrome c oxidase). 
Even though low concentrations can activate survival 
pathways, high concentrations of CO can increase 
mitochondrial oxidative stress, inhibit mitochondrial 
electron transport chain and protein synthesis and maybe 
activate apoptotic pathways in predisposed cells [60–65]. 
It has been shown that exogenous CO reduces glucose 
consumption as well as increases oxygen consumption, 
indicating a CO-induced improvement in oxidative 
phosphorylation levels [59]. CO can also limit prostate 
cancer progression by manipulating cell metabolism, 
thus sensitizing cancer cells to chemotherapy via 
promoting an anti-Warburg effect. Indeed, CO can target 
the mitochondrial activity, inducing higher oxygen 
consumption levels and free radical generation, thus 
leading to mitochondrial collapse, cancer cell growth 
inhibition and maybe apoptosis, induced potentially by 
chemotherapy [66]. Finally it has been demonstrated that 
CO released from a novel CORM (CORM-401) induced 
uncoupling of mitochondrial respiration and repression 
of glycolysis, which could lead to the inhibition of 
pathological angiogenesis [67].
CORMs were tested for their effect on the glycolysis 
levels of MDA-MB-231 cells. It has been previously 
shown that CO release from low concentrations of 
CORM-3 interact with the mitochondrial respiratory chain 
by uncoupling proteins and also with adenine dinucleotide 
transporters leading to disruption of the membrane 
potential. Ruthenium compounds have demonstrated 
significant mitochondrial toxicity suggesting that the 
Ru core might also be responsible for the impairment 
of complex I and IV activity [68, 69]. Therefore, our 
results could be explained by supporting the hypothesis 
that the Ru core of CORM-2 along with the CO reduce 
the glycolytic metabolism of TNBC cells by interfering 
with the mitochondrial activity, inhibiting proteins of the 
respiratory chain and leading to electron leakage and ROS 
production.
It has been previously shown that suppression 
of HO-1 expression can impede the proliferation and 
viability of pancreatic cancer cells [70], as well as the 
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survival and growth of hepatocellular carcinoma [71] 
and prostate cancer cells [72]. However, in other studies 
HO-1 silencing was oppositely reported to increase 
tumour growth [73], pointing towards a rather complex 
and tumour type-specific role. Most of the increasing 
evidence suggest a link between lower expression 
of HO-1 and higher sensitivity of cancer cells [65]. A 
study done by Taillé et al. [53] suggested no change 
in HO-1 expression after 24 h treatment with up to 10 
µM CORM-2 in airway smooth muscle cells but shorter 
treatments against TNBC cells have not been explored 
according to our knowledge. Our results showed a 
downregulating activity of CORMs towards HO-1 that 
was significant for CORMs -1 and -2 but failed to reach 
significance for CORM-3. However, the pattern observed 
for these complexes was not shared by CORM-A1, 
which markedly increased HO-1 expression in TNBC 
cells. These observations suggest two different concepts: 
1) that transition-metal based CORMs can decrease the 
expression of HO-1 in TNBC, a mechanism not followed 
by the non-transition metal-based CORM-A1, and 2) that 
this downregulation might lead to a higher sensitivity 
of these cells towards other chemotherapeutic or anti-
angiogenic agents, based on previous observations for 
other tumour types [70].
Nevertheless, it seems that CORM-2 is the best 
analogue of the four CORMs we tested, pointing towards 
a mechanism of action targeting the VEGF expression in 
TNBC cells and the activation of ERK1/2 and other proteins 
in ECs. CORM-2 was also shown to reduce the glycolytic 
metabolism of TNBC cells, downregulate HO-1 and inhibit 
EC migration. Tube formation was significantly reduced 
after treatment with conditioned media from CORM-
2-treated cancer cells and eliminated completely after 
direct treatment with this CORM. The observed abilities 
probably cannot be solely attributed to the released CO, 
otherwise a very similar effect would have been reported 
for all tested CORMs since they are reported to release 
comparable amounts [74–78]. Our hypothesis is that the 
Ru core might also play an important role in the observed 
results, as well as the dimeric form of CORM-2 that can 
potentially enhance interactions with cellular targets. Most 
studies use CO-depleted molecules as negative controls for 
their experiments and indeed find a significantly decreased 
efficacy upon CO elimination [21, 41]. On the other hand, 
in our study very similar molecules such as CORM-2 and 
CORM-3 showed various differences in their actions, 
determining CORM-2 as a more effective compound. 
Therefore, we firmly believe that the results reported here 
depend both on the metal centre and the released CO, but 
a future more in-depth study remains to determine the 
true contribution of each factor by comparing Ru-based 
molecules without CO ligands and Ru-based CORMs with 
different ligands than in CORM-2 and CORM-3.
In summary, ongoing experiments remain to shed 
more light on the specific cellular targets that relate 
CORM-2 to the VEGF expression mechanism in TNBC 
cells and to specific proteins in the VEGFR2 pathway of 
ECs. Based on these observations though, CORM-2 can 
be suggested for a holistic approach against malignant 
angiogenesis in TNBC, due to its interference with several 
steps of the angiogenic process and the metabolism of 
TNBC cells. When a more detailed mechanism of action 
is discovered for CORM-2, several combination therapies 
can be explored that will be able to target vital components 
of malignant angiogenesis succeeding in eliminating it.
MATERIALS AND METHODS
Reagents
Recombinant human VEGF-A was purchased from 
R&D Systems (Minneapolis, USA). We obtained the 
mouse anti-phospho-ERK1/2 (Y204) and anti-GAPDH 
from Santa Cruz Biotechnology (Heidelberg, Germany). 
The anti-phospho-VEGFR-2 (Y1175), anti-phospho-Src 
(Y419) and anti-phospho-FAK (Y397) were obtained 
from Abcam (Cambridge, UK). The rabbit anti-HO-1 
was purchased from Enzo Life Sciences (Exeter, UK). 
All antibodies used in the study are summarised in Table 
1. Basement membrane matrix was from BD Biosciences 
(Oxford, UK). All other cell culture reagents and 
chemicals, including dimanganese decacarbonyl Mn2CO10 
(CORM-1), tricarbonyldichlororuthenium (II) dimer 
[Ru(CO)3Cl2]2 (CORM-2), tricarbonylchloro(glycinate)-
ruthenium (II) Ru(CO)3Cl-glycinate (CORM-3) and sodium 
boranocarbonate Na2(H3BCO2) (CORM-A1) were obtained 
from Sigma-Aldrich (Dorset, UK), unless otherwise stated.
Table 1: Antibodies used in the study
Antibody name Molecular weight (kDa) Phosphorylation site
Final concentration 
used Product code
Mouse anti-GAPDH 37 - 0.2 µg/mL SC-32233
Mouse anti-pERK1/2 42/44 Y204 0.4 µg/mL SC-7383
Rabbit anti-pVEGFR2 152 Y1175 1.49 µg/mL Ab-194806
Rabbit anti-pSrc 60 Y419 0.538 µg/mL Ab-185617
Rabbit anti-HO-1 32 - 1.0 µg/mL HC3001
Rabbit anti-pFAK 119 Y397 1.0 µg/mL Ab-81298
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Cell culture
MDA-MB-231, MDA-MB-436 and HECV cell 
lines were routinely maintained in Dulbecco’s Modified 
Eagle’s medium (DMEM/Ham’s F-12 with L-Glutamine) 
supplemented with 10% heat-inactivated foetal bovine 
serum (FBS) and 1% of antibiotic cocktail mix. MCF-10A 
cells were routinely maintained in Mammary Epithelial 
Basal Medium (MEBM, Lonza, Gloucestershire, UK) 
supplemented with the recommended growth supplements 
(MEGM kit) (Lonza), 1% antibiotic cocktail mix and 
100 ng/mL cholera toxin. HUVEC cells were routinely 
maintained in Endothelial Cell Growth Basal Medium-2 
(EBM-2, Lonza) supplemented with the recommended 
growth supplements (EGM-2 BulletKit) (Lonza), 1% 
antibiotic cocktail mix and 2% FBS. All the cells were 
grown to confluence in 25 cm3 or 75 cm3 culture flasks 
loosely capped (Greiner Bio-One Ltd., Gloucestershire, 
UK) at 37°C in 5% CO2 and 95% humidity. The flasks 
were left to reach adequate confluence before conducting 
each experiment, unless otherwise stated.
ELISA for VEGF quantification in supernatant 
of cell cultures
Upon reaching adequate confluence, the normal 
media of a cell culture was replaced with fresh media 
containing the corresponding concentration of CORMs 
or 1% DMSO or no treatment and the cells were left 
in the normal incubator for 6 h, 12 h or 24 h. After the 
indicated incubation time, the supernatant of the flask was 
collected, centrifuged and aliquoted in 1 mL Eppendorf 
tubes that were kept at –80°C until required. Protein was 
also extracted from each flask, quantified using the Bio-
Rad DC Protein Assay kit (Bio-Rad laboratories, Hemel 
Hempstead, UK) and used for normalization of the results. 
Each aliquot was thawed and used only once and the 
VEGF content was quantified using the human VEGF 
ELISA kit (Life Technologies Ltd., Paisley, UK) following 
the manufacturer’s instructions.
Expression of phosphorylated proteins in VEGF-
stimulated HUVEC cells
HUVEC cells were seeded in 6-well plates and upon 
reaching adequate confluence (~80%), they were serum 
starved for 12 h. Treatments of 100 µM CORMs or 1% 
DMSO or serum free media were added to each well and 
the cells were left in the normal incubator for 15 min. After 
that, 100 ng/mL VEGF was added for further 5 min. The 
supernatant of the well was then discarded and the total 
protein was extracted from each well and quantified. The 
lysate was used either for ELISA for the quantification 
of pY1175 following the manufacturer’s instructions or 
for Western blot analysis as reported previously. All the 
antibodies used in this study are listed in Table 1.
Conditioned media preparation and tube 
formation assay
Upon reaching adequate confluence, the normal 
media of an MDA-MB-231 cell culture was replaced with 
fresh media containing the corresponding concentration of 
CORMs or 1% DMSO or no treatment and the cells were 
left in the normal incubator for 6 h, 12 h or 24 h. After the 
indicated incubation time, the supernatant of the flask was 
collected, centrifuged and aliquoted in 1 mL Eppendorf 
tubes that were kept at –80°C until required. HECV cells 
were seeded on top of a pre-set layer of Matrigel in each 
well of a 96-well plate. The plate was left in the normal 
incubator for cells to adhere and then the full media was 
replaced with serum free media containing conditioned 
media from treated MDA-MB-231 cells or direct treatments 
with CORMs. After 6 h, the wells were imaged using 
a Leica DM 1000 LED microscope capturing at least 3 
images/well in random areas. The images were analysed 
using the ImageJ software and the percentage of total tube 
length compared to the wells that received conditioned 
media from vehicle treated MDA-MB-231 cells or the 
vehicle treated group was calculated from three independent 
experiments performed in triplicate.
Traditional scratch wound assay
HECV cells were seeded in a 24-well plate and left 
to form a confluent monolayer. The cells were then washed 
with PBS, wounded with a pipette tip, re-washed twice and 
treated with normal media containing CORMs or vehicle 
or no treatment for 24 h. Photos were taken at 0 h, 8 h, 12 h 
and 24 h after wounding using a Leica DM 1000 LED 
microscope (Leica Microsystems, Milton Keynes, UK) 
(5x objective). Migration distances were measured using 
ImageJ software (National Institutes of Health, NY, USA) 
and percentage of wound confluence compared to vehicle 
was calculated from three independent experiments 
performed in triplicate.
MTT assay
The MTT assay was conducted as described 
previously [79]. Briefly, 5 × 103 cells were seeded in 
normal medium in a 96-well plate and left to attach. The 
cells were then treated with increasing concentrations 
of CORMs or vehicle for 72 h. Then MTT solution was 
added for further 4 h, the medium was removed, and 
acidified isopropanol was used to dissolve the purple 
formazan crystals. The absorbance of the test plate was 
read at 540 nm and an identical blank plate was used to 
subtract any background absorbance from the test plate 
absorbance. The absorbance for each compound was 
subsequently normalized to the vehicle treated cells prior 
to plotting. Data was statistically analysed using non-
linear regression (curve fit) to calculate the IC50 value of 
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each compound against each cell line in GraphPad Prism 
(GraphPad Prism Version 6.0, www.graphpad.com).
Glycolysis Stress test with the Seahorse 
Extracellular XFe Flux Analyser
The glycolysis levels of the cells were measured 
using the Seahorse Extracellular XFe Flux Analyser as 
reported previously and according to the manufacturer’s 
instructions [80]. Briefly 40,000 cells/well were seeded in 
a Seahorse XF24 Cell Culture Microplate. The Seahorse 
Base medium included 1 mM glutamine, was adjusted to 
pH 7.35 and was kept at 37°C after filtration. The normal 
media of the cells was removed and Glycolysis media was 
added before the plate was left in a CO2-free incubator for 
1 h. All the injections prepared meanwhile were loaded 
on the injection plate and both plates were inserted and 
the experiment followed the suggested protocol. After the 
experiment, a protein quantification assay was performed 
and the results were normalized to protein concentration/
well. The glycolysis levels are presented as x-fold increase 
in glycolysis rates measured in mpH/min (ECAR) from 
three independent experiments performed in triplicate.
HO-1 expression in MDA-MB-231 cells
Upon reaching adequate confluence, the normal 
media of a cell culture was replaced with fresh media 
containing the corresponding concentration of CORMs or 
1% DMSO or no treatment and the cells were left in the 
normal incubator for 12 h. After that, the supernatant of 
the flask was discarded and the total protein was extracted 
from each flask and subjected to western blotting as 
reported previously [81]. After the SDS-PAGE, the 
proteins were transferred onto nitrocellulose membrane 
which was then blocked and probed with the relevant 
primary and the corresponding peroxidase-conjugated 
secondary antibodies. The protein bands were eventually 
visualized using the chemilluminescence detection system 
EZ-ECL (Biological Industries, Cromwell, USA). All the 
antibodies used in this study are listed in Table 1.
Statistical analysis
Statistical analysis was performed using GraphPad 
Prism. Unpaired Student’s t-test with Welch’s correction 
for two groups, non-parametric Mann-Whitney t-test for 
western blot and two-way ANOVA for multiple groups 
were performed to check for statistical significance, with 
a p-value of <0.05 considered statistically significant. 
Asterisk notation (*) was used to identify significances: *p 
< 0.05, **p < 0.01 and ***p < 0.001.
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